{"nctId":"NCT02337062","briefTitle":"Phase IIIb Study of APD421 in Combination as PONV Prophylaxis","startDateStruct":{"date":"2015-02"},"conditions":["PONV"],"count":1147,"armGroups":[{"label":"APD421 + standard anti-emetic","type":"EXPERIMENTAL","interventionNames":["Drug: APD421"]},{"label":"Placebo + standard anti-emetic","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"APD421","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age\n* Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure\n* Patients with at least 3 \"Apfel\" risk factors for PONV\n\nExclusion Criteria:\n\n* Patients scheduled to undergo transplant surgery\n* Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block\n* Patients who are expected to remain ventilated for a period after surgery\n* Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Complete Response","description":"Complete response defined as no emesis and no use of rescue medication in the 24 hour period after end of surgery (defined as wound closure)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"268","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Emesis","description":"Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Receiving Rescue Medication","description":"Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":null},{"groupId":"OG001","value":"284","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Nausea","description":"Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. \"Any nausea\" means a score ≥ 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"286","spread":null},{"groupId":"OG001","value":"335","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Significant Nausea","description":"Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. \"Significant nausea\" means a score ≥ 4.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"274","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Violation of Criteria for PONV","description":"Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"821.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":572},"commonTop":["Nausea","Procedural Pain"]}}}